COLORADO BLOOD CANCER INSTITUTE
🇺🇸United States
Clinical Trials
4
Active:0
Completed:0
Trial Phases
2 Phases
Phase 2:3
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (75.0%)Phase 3
1 (25.0%)Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Colorado Blood Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT02178683
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
Phase 2
- Conditions
- Graft Failure
- Interventions
- Procedure: Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donorsProcedure: TBI
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Colorado Blood Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00472329
- Locations
- 🇺🇸
Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado, United States
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation
Phase 2
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myeloid LeukemiaNon-Hodgkin LymphomaMyelodysplastic Syndromes
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2006-06-26
- Lead Sponsor
- Colorado Blood Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00328237
- Locations
- 🇺🇸
Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado, United States
Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor
Phase 2
- Conditions
- Multiple MyelomaLymphomaAcute Myelogenous LeukemiaAcute Lymphocytic LeukemiaMyelodysplastic Syndrome
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2008-02-08
- Lead Sponsor
- Colorado Blood Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00304720
- Locations
- 🇺🇸
Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado, United States
News
No news found